GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
|
|
- Esmond Lynch
- 5 years ago
- Views:
Transcription
1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. GSK Medicine: GlaxoSmithKline (GSK) Biologicals H5N1 Pandemic Influenza Vaccine (GSK A) Study Number: (FLU Q-PAN-022) Title: Safety and tolerability of GSK A vaccine in adults at occupational risk for influenza A (H5N1) exposure. GSK A (H5N1): GlaxoSmithKline (GSK) Biologicals adjuvanted A/Indonesia/5/2005 (H5N1) vaccine. Rationale: The purpose of this study was to assess the safety and tolerability of H5N1 vaccine in an adult population at occupational risk for influenza A (H5N1) exposure. This CTRS presents data up to Day 51. The study is ongoing and the CTRS will be updated with results from later timepoint(s) once the data is available. Phase: III Study Period:22 March 2013 to 07 April 2014 (Day 51) Study Design: Open-label, multi-center, single country, single group study. Centres: 6 centers in United States Indication: Immunization of adults 18 years of age and older against H5N1 influenza. Treatment: The study groups were as follows: H5N1 Group: Subjects received 2 doses of H5N1 vaccine at Days 0 and 21. For some pre-specified analyses, subjects were categorized by age groups as: H5N1 Adults Group: Subjects aged years received 2 doses of H5N1 vaccine at Days 0 and 21. H5N1 Elderly Group: Subjects aged >64 years received 2 doses of H5N1 vaccine at Days 0 and 21. The vaccine was administered intramuscularly in the deltoid region of arm (Non-dominant arm at Day 0 and Dominant arm at Day 21). Objectives: To describe the safety of H5N1 vaccine in terms of solicited local and general adverse events for 7 days and all unsolicited AEs for 21 days after each vaccination. Primary Outcome Variable(s): Solicited local and general symptoms overall and by age category (18-64 and >64 years of age) Occurrence of each solicited local symptom during a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccination Occurrence and relationship to vaccination of each solicited general symptom during a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccination Unsolicited adverse events overall and by age category (18-64 and >64 years of age): Occurrence and relationship to vaccination* of unsolicited adverse events (AEs) within 21 days after each dose. *At the time of writing this CTRS, result of this outcome was not available. The CTRS will be updated when this results become available Secondary Outcome Variable(s)*: Quality of life measures as assessed overall and by age category (18-64 and >64 years of age): Change from baseline in the daily SF-36v2 scores (subscale component scores, summary scores and utility scores) by solicited local and general adverse event status after the first vaccine dose Change from baseline (as collected by both the SF-36v2 daily and weekly questionnaires) in the following parameters: Physical functioning Physical-health related role limitations Bodily pain General health Vitality Social functioning Emotional health related role limitations Mental health Change from baseline in physical and mental component summary measures based on the data collected in both daily and weekly SF-36v2 questionnaires
2 Change from baseline in SF-6D utility measures based on the data collected in both daily and weekly SF-36v2 questionnaires Change from baseline in the weekly SF-36v2 scores (subscale component scores, summary scores and utility scores) by solicited local and general adverse event status after the first and second vaccine doses In the case of an adverse event report during the 7 days after dose 1, time to return to baseline in the daily and weekly SF36v2 scores To concurrently assess psychometric validity and internal consistency of the daily SF-36v2 questionnaire, the following additional endpoints will be assessed: Quantitative differences between SF-36v2 questionnaire responses, and the solicited local and general adverse event data provided on diary cards. Occurrence and relationship to vaccination of Medically Attended Adverse Events (MAEs)**, Potential Immune- Mediated Diseases (pimds), Serious Adverse Events (SAEs) and adverse pregnancy outcomes** during the entire study period. *This summary contains only safety data until Day 51 of this study. It will be updated when results for other outcome variables become available. **At the time of writing this CTRS, result of these outcomes were not available. The CTRS will be updated when this result become available Statistical Methods: The analyses were performed on the Total Vaccinated cohort. - The Total Vaccinated cohort included all vaccinated subjects for whom safety data were available. Analysis of Safety : The analysis was performed on the Total Vaccinated cohort. The percentages of subjects reporting each individual solicited local and general AEs during a 7-day (Days 0-6) follow-up period after each vaccination and across doses were tabulated with exact 95%CI. The same tabulation was performed for grade 3 solicited AEs and for solicited general AEs assessed by the investigators as causally related to vaccination. The percentage of subjects with at least one report of an unsolicited AEs, classified by the Medical Dictionary for Regulatory Activities (MedDRA) preferred term, during the 21-day (Days 0-20) follow-up period after each vaccination was tabulated for the treatment group. The percentages of subjects reporting SAEs and pimds, according to MedDRA preferred terms were tabulated up to Day 51. SAEs and pimds classified according to MedDRA preferred terms and assessed by the investigators to be causally related to vaccination were also reported. Study Population: Healthy male and female adults 18 years of age at time of first study vaccination and who were at risk of occupational exposure to H5N1 influenza viruses based on exposure, or potential exposure during either (a) laboratory operations with live H5N1 virus, (b) production of H5N1 vaccines, or (c) conduct of epidemiological investigations of H5N1 cases; were included in this study. Female subjects of childbearing potential had to practice adequate contraception for 30 days prior to vaccination, to have a negative pregnancy test on the day of first vaccination and had agreed to continue adequate contraception during the entire treatment period for 2 months after completion of the vaccination series. Subjects with significant risk of complications from intramuscular injections due to disorder of coagulation were excluded from this study. Written informed consent was obtained from the subjects prior to study entry. Number of Subjects H5N1 Adults Group H5N1 Elderly Group H5N1 Group Planned, N Not Applicable Not Applicable 150 Randomised, N (Total Vaccinated cohort) Completed, n (%) Day (98.0) 1 (100) 49 (98.0) Total Number Subjects Withdrawn, n (%) 1 (2.0) 0 (0.0) 1 (2.0) Withdrawn due to Adverse Events n (%) 0 (0.0) 0 (0.0) 0 (0.0) Withdrawn due to Lack of Efficacy n (%) Not Applicable Not Applicable Not Applicable Withdrawn for other reasons n (%) 1 (2.0) 0 (0.0) 1 (2.0) Demographics H5N1 Adults Group H5N1 Elderly Group H5N1 Group N (Total Vaccinated Cohort) Females, n (%) 28 (57.1) 0 (0.0) 28 (56.0) Males, n (%) 21 (42.9) 1 (100) 22 (44.0) Mean Age, years (SD) 42.5 (10.7) 85.0 (Not Applicable*) 43.3 (12.2) Median Age, years (minimum, maximum) 41 (26, 62) 85 (85, 85) 42 (26, 85) White - Caucasian / European Heritage, n (%) 33 (67.3) 1 (100) 34 (68.0) African Heritage / African American, n (%) 3 (6.1) 0 (0.0) 3 (6.0) Asian - East Asian Heritage, n (%) 3 (6.1) 0 (0.0) 3 (6.0)
3 Asian - Japanese Heritage, n (%) 3 (6.1) 0 (0.0) 3 (6.0) Asian - South East Asian Heritage, n (%) 3 (6.1) 0 (0.0) 3 (6.0) *as this group has only 1 subject, SD cannot be calculated. Primary Outcome Results: Number (%) of subjects reporting solicited local symptoms during the 7-day (Days 0-6) postvaccination period following each dose and across doses (Total Vaccinated cohort) H5N1 Adults Group H5N1 Elderly Group H5N1 Group 95 % CI 95 % CI 95 % CI Symptom Intensity N n % LL UL N n % LL UL N n % LL UL Dose 1 Pain Any Grade Redness Any Swelling Any Dose 2 Pain Any Grade Redness Any Swelling Any Across doses Pain Any Grade Redness Any Swelling Any N = number of subjects with at least one documented dose; n/% = number/percentage of subjects reporting the symptom at least once 95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit Any = occurrence of any local symptom regardless of their intensity grade Grade 3 pain = Significant pain at rest. Prevents normal every day activities Primary Outcome Results: Number (%) of subjects reporting solicited general symptoms during the 7-day (Days 0-6) postvaccination period following each dose and across doses (Total Vaccinated cohort) H5N1 Adults Group H5N1 Elderly H5N1 Group Group 95 % CI 95 % CI 95 % CI Symptom Intensity/Relationship N n % LL UL N n % LL UL N n % LL UL Dose 1 Fatigue Any Related Gastrointestinal Any Related Headache Any Related Joint pain Any Related Muscle ache Any Related
4 Shivering (chills) Any Related Sweating Any Related Temperature/(Oral) 38.0 C C Related Dose 2 Fatigue Any Related Gastrointestinal Any Related Headache Any Related Joint pain Any Related Muscle ache Any Related Shivering (chills) Any Grade Related Sweating Any Grade Related Temperature/(Oral) 38.0 C C Related Across doses Fatigue Any Related Gastrointestinal Any Grade Related Headache Any Grade Related Joint pain Any Related Muscle ache Any Related Shivering (chills) Any Related Sweating Any Related
5 Temperature/(Oral) 38.0 C C Related N = number of subjects with at least one documented dose; n/% = number/percentage of subjects reporting the symptom at least once 95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit Any = occurrence of any general symptom regardless of their intensity grade or relationship to vaccination Grade 3 symptom = symptom that prevented normal activity Related = symptom assessed by the investigator as causally related to the study vaccination Secondary Outcome Variable(s): Number (%) of subjects with pimds up to Day 51 (Total Vaccinated cohort) All pimds H5N1 Adults Group H5N1 Elderly Group Subjects with any pimd(s), n (%) 0 (0.0) 0 (0.0) Subjects with related pimd(s), n (%) 0 (0.0) 0 (0.0) Safety Results: Number (%) of subjects with unsolicited AEs reported during the 21 day (Days 0-20 post dose 1 and Days post dose 2) post vaccination period (Total Vaccinated cohort) Most frequent adverse events - On-Therapy (occurring within days 0-20 and days following vaccination) H5N1 Adults Group H5N1 Elderly Group Subjects with any AE(s), n (%) 10 (20.4) 0 (0.0) Acute sinusitis 1 (2.0) - Axillary pain 1 (2.0) - Cough 1 (2.0) - Dermatitis allergic 1 (2.0) - Epistaxis 1 (2.0) - Gastrointestinal disorder 1 (2.0) - Injection site pruritus 1 (2.0) - Intervertebral disc degeneration 1 (2.0) - Labile hypertension 1 (2.0) - Lymphadenopathy 1 (2.0) - Menstruation irregular 1 (2.0) - Oropharyngeal pain 1 (2.0) - Pain in jaw 1 (2.0) - Rectal haemorrhage 1 (2.0) - Upper respiratory tract infection 1 (2.0) - -: Adverse event absent Safety Results: Number (%) of subjects with serious adverse events reported up to Day 51 (Total Vaccinated cohort) All SAEs Subjects with any SAE(s), n (%) [n assessed by the investigator as related] Fatal SAEs Subjects with fatal SAE(s), n (%) [n assessed by the investigator as related] H5N1 Adults Group H5N1 Elderly Group 0 (0.0) [0] 0 (0.0) [0] H5N1 Adults Group H5N1 Elderly Group 0 (0.0) [0] 0 (0.0) [0] Conclusion: During the 7-day (Days 0-6) post-vaccination period, pain was reported for 45 (91.8%) subjects in H5N1 Adults Group and 1 (100%) subject in H5N1 Elderly Group; redness and swelling was reported for 6 (12.2%) and 7(14.3%) subjects respectively, in H5N1 Adults Group. No redness and swelling was reported in H5N1 Elderly Group. During the 7-day (Days 0-6) post-vaccination period, fatigue was reported for 27 (55.1%) subjects, gastrointestinal was reported for 12 (24.5%) subjects, headache was reported for 20 (40.8%) subjects, joint pain was reported for 14 (28.6%) subjects, muscle ache was reported for 33 (67.3%) subjects, shivering (chills) was reported for 10 (20.4%) subjects, sweating was reported for 7 (14.3%) subjects and fever was reported for 1 (2.0%) subject in the H5N1 Adults Group. No
6 solicited general symptoms were reported in the H5N1 Elderly Group. Muscle ache was considered to be causally related to the vaccination in 31 (62.0%) subjects in H5N1 Adults Group. During the 21 day post vaccination period, at least one unsolicited AE was reported for 10 (20.0%) subjects in H5N1 Adults Group and none in H5N1 Elderly Group. No serious adverse events were reported up to Day 51. Date updated: 09-April-2015
Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAnalysis of immunogenicity
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationD-QIV_LP 6-35m Group: Subjects aged 6-35 months received 1 or 2 doses of D-QIV_IP vaccine depending on vaccine-priming
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAnalysis of safety The analysis was performed on the Total Vaccinated cohort.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
he study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationLong-term follow-up at Month 198: 21 October 2008 to 07 December Long-term follow-up at Month 186: 01 October 2007 to 19 December 2008
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMenC. MenW MenY
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationFor the additional vaccination phase
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationsubjects having anti-hav antibody concentrations 100 miu/ml at the pre- additional vaccination time point.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable(s):
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSynopsis of study HBV-314 BST 280 (108988)
Synopsis of study HBV-314 BST 280 (108988) Pharmaceutical entrepreneur: GlaxoSmithKline GmbH & Co. KG Prinzregentenplatz 9 81675 Munich Germany Personal identifiable data of investigators (name / full
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medication: Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationvaccination. Children enrolled in these clusters between 6 weeks and 6 months of age received a 2-dose primary vaccination schedule.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Periods: Study Design: Centers: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTo demonstrate that DTPa-HBV-IPV/Hib-MenC-TT co-administered with 10Pn, is non-inferior to DTPa-HBV-IPV/Hib coadministered
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: GlaxoSmithKline Biologicals (GSK) AS03-adjuvanted monovalent pandemic influenza H5N1 or H1N1 vaccines manufactured in Quebec or Dresden
GSK Medicine: GlaxoSmithKline Biologicals (GSK) AS03adjuvanted monovalent pandemic influenza H5N1 or H1N1 vaccines manufactured in Quebec or Dresden Study No.: Flu QPAN (H5N1+ H1N1) Integrated summary
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Note: Phase: Study Period: Study Design: Centres: Indication: Treatment: Hib-MenCY F1 Group Hib-MenCY F2 Group
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Study vaccines Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSynopsis for study HAV-112 EXT M210 (110678)
Synopsis for study HAV-112 EXT M210 (110678) Pharmaceutical entrepreneur: GlaxoSmithKline GmbH & Co. KG Prinzregentenplatz 9 81675 Munich Germany Personal identifiable data of investigators (name / full
More information- Infanrix hexa (DTPa-HBV-IPV/Hib): GSK Biologicals combined diphtheria, tetanus, acellular pertussis, hepatitis
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationNovartis Vaccines and Diagnostics S.r.l.
27NOV15 Page 1 of 11 Sponsor: Investigational Product: Novartis Vaccines and Diagnostics S.r.l., Adjuvanted trivalent influenza virus vaccine (surface antigen, inactivated, adjuvanted with MF59C.1, egg-derived)
More informationStudy Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHBV-2 Group: neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (Part of
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationNovartis Vaccines and Diagnostics S.r.l
28 OCT 15 Page 1 of 11 Sponsor: Investigational Product: Indication: Protocol Number: Protocol Title: Phase of Development: and Diagnostics S.r.l ativ (Adjuvanted trivalent influenza virus vaccine (surface
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SHINGRIX safely and effectively. See full prescribing information for SHINGRIX. SHINGRIX (Zoster
More informationmg 25 mg mg 25 mg mg 100 mg 1
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationIT S A LIFESAVER EVERY YEAR FLU CAUSES SEVERE ILLNESS AND DEATH. GET YOUR FLU VACCINE NOW. IF YOU ARE: worker
FLU VACCINE Information FOR Health care workers EVERY YEAR FLU CAUSES SEVERE ILLNESS AND DEATH. IF YOU ARE: A health care worker Over 65 Have a longterm illness Pregnant GET YOUR FLU VACCINE NOW. IT S
More informationWe ll be our lifesaver. We ll get the flu vaccine.
We ll be our lifesaver. We ll get the flu vaccine. The flu vaccine is a lifesaver for healthcare workers and the people they care for. www.immunisation.ie Flu Vaccine 2017-18 Healthcare workers prevent
More informationWe ll be our own lifesavers. We ll get the flu vaccine.
We ll be our own lifesavers. We ll get the flu vaccine. The flu vaccine is a lifesaver for older people and those with long-term health conditions. www.immunisation.ie Flu Vaccine 2017-18 What is seasonal
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTreatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14)
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:
GSK Medicine: abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) Study Number: 201147 Title: A IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationA FLU SHOT CREATED DIFFERENTLY.
Indication and Usage for FLUCELVAX (Influenza Vaccine) A FLU SHOT CREATED DIFFERENTLY. FLUCELVAX (Influenza Vaccine) rethinking flu protection. FLUCELVAX was the first FDA-approved influenza vaccine made
More informationStudy No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s):
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationI M VACCINATING FOR TWO NOW. IT S A LIFESAVER. Pregnant women and their babies are at risk from flu. Protect you and your baby - get your flu vaccine.
I M VACCINATING FOR TWO NOW. Pregnant women and their babies are at risk from flu. Protect you and your baby - get your flu vaccine. IT S A LIFESAVER www.im munisation.ie For more information, talk to
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No: Title: Rationale: . Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationUMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPatient Group Direction For The Administration Of H1N1 (Swine Flu) vaccine
n Patient Group Direction For The Administration Of H1N1 (Swine Flu) vaccine October 2009 PGD version template-2009.1 Page 1 of 8 Rationale Patient Group Direction For The Administration Of H1N1 (Swine
More informationStudy No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine Study Number: Title: Rationale Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and nonapproved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
Study No.: 29060/717 Title: A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder Rationale: In most trials investigating
More informationWe ll be our lifesaver. We ll get the flu vaccine.
We ll be our lifesaver. We ll get the flu vaccine. www.hse.ie/flu Flu Vaccine 2018-19 Healthcare workers prevent the spread of flu and save lives every year by getting vaccinated with the flu vaccine.
More informationSecondary Outcome/Efficacy Variable(s):
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information2.0 Synopsis. Adalimumab M Clinical Study Report R&D/04/900. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2. Synopsis Abbott Laboratories Name of Study Drug: Name of Active Ingredient: Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Phase
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSponsor Novartis. Generic Drug Name Pasireotide. Therapeutic Area of Trial Cushing s disease. Protocol Number CSOM230B2208E1
Sponsor Novartis Generic Drug Name Pasireotide Therapeutic Area of Trial Cushing s disease Protocol Number CSOM230B2208E1 Title Extension to a multicenter, open-label study to assess the safety and efficacy
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Trial result: Page 1 / 6
SYNOPSIS Title of Study: Study Number Serological Study of FluvalAB Influenza Vaccine (Trivalent, Seasonal) Intended to Use in the 2010/2011 Vaccination Season FluvalAB-H-YL2010 EudraCT Number 2010-021071-83
More information